Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nao-Xue-Shu oral liquid for postoperative intracranial hematoma
ChiCTR1800017981Phase 3Completed
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Mar 2018
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of naoxueshu in intracerebral hemorrhage (ICH) (2 arms), sponsored by The First Hospital of Fujian Medical University. Primary endpoints: Proportion of hematoma volume and Serious adverse events. Started Mar 2018; status: completed.
02
Drugs
naoxueshu
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on ChiCTR1800017981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800017981.